Short-term Efficacy of Telbivudine Versus Entecavir for HBeAg-positive Chronic Hepatitis B:a Meta-Analysis
WANG Xiao-li,TIAN Jin-hui,YANG Ke-hu,CHEN Qing-feng,CHEN Hong
DOI: https://doi.org/10.3969/j.issn.1009-7708.2012.02.001
2012-01-01
Abstract:Objective To evaluate the efficacy of telbivudine versus entecavir in the short-term treatment of HBeAg-positive chronic hepatitis B.Methods Cochrane Library,PubMed,EMBASE,Chinese Biomedical Database,WanFang Database Online,China Journal Full-text Database were searched to retrieve the published randomized controlled trials(RCTs) involving telbivudine versus entecavir for HBeAgpositive chronic hepatitis B.Two reviewers independently screened the studies for eligibility,evaluated the quality and extracted the data from the eligible studies with Cochrane Handbook 5.0.2.Meta-analysis was performed by using RevMan5.1.1 software.Results Nine eligible RCTs with 875 patients were included in this analysis.Meta-analysis showed that telbivudine was more effective than entecavir in terms of loss of serum HBeAg at 12 weeks[OR = 0.16,95%CI(0.08,0.30)]and 24 weeks[OR = 0.64,95%CI(0.44,0.92)],in terms of HBeAg seroconversion at 12 weeks[OR = 0.25,95%CI(0.13,0.49)]and 24 weeks[OR= 0.54,95%CI(0.37,0.81)].But telbivudine was more likely associated with increased level of creatinine phosphokinase(CK) than entecavir[OR = 0.12,95%CI(0.05, 0.27)].Telbivudine was comparable to entecavir in terms of loss of serum HBV DNA at 12 weeks[OR = 1.08,95%CI(0.81,1.43)] and 24 weeks[OR = 0.80,95%CI(0.60,1.07)];serum alanine aminotransferase(ALT) normalization at 12 weeks[OR= 1.08,95% CI(0.75,1.56)]and 24 weeks[OR = 0.90,95%CI(0.62,1.32)];gastrointestinal reactions[OR = 2.42,95%CI(0.61,9.53)],or fatigue[OR= 1.46,95%CI(0.42,5.04)].Conclusions In HBeAg-positive chronic hepatitis B patients,telbivudine is more effective than entecavir in loss of serum HBeAg,HBeAg seroconversion,but telbivudine is more likely associated with increased CK level than entecavir.No significant difference was found between telbivudine and entecavir in terms of loss of serum HBV DNA,serum ALT normalization,gastrointestinal reactions or fatigue.